Accessibility Statement Skip Navigation
  • Resources
  • Blog
  • Journalists
  • +44 (0)20 7454 5110
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All Public Company News
      • All Multimedia News
      • View All News Releases

      • Regulatory News

      • D/A/CH Regulatory News
      • UK Regulatory News
      • View All Regulatory News

  • Business & Money
      • Auto & Transportation

      • Aerospace & Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads & Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking & Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers & Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalisation
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls & Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil & Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defence
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation & Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking & Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers & Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines & Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics & Personal Care
      • Fashion
      • Food & Beverages
      • Furniture & Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewellery
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks & Tourist Attractions
      • Gambling & Casinos
      • Hotels & Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Animal Welfare
      • Corporate Social Responsibility
      • Economic News, Trends & Analysis
      • Education
      • Environmental
      • European Government
      • Labour & Union
      • Natural Disasters
      • Not For Profit
      • Public Safety
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • SocialBoost
  • Rooms
    • MediaRoom
    • ESG Rooms
  • AI Tools
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Hamburger menu
  • Cision PR Newswire UK provides press release distribution, targeting, monitoring, and marketing services
  • Send a Release
    • Phone

    • +44 (0)20 7454 5110 from 8 AM - 5:30 PM GMT

    • ALL CONTACT INFO
    • Contact Us

      +44 (0)20 7454 5110
      from 8 AM - 5:30 PM GMT

  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • News in Focus
    • Browse News Releases
    • Regulatory News
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
    • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • Cision Communications Cloud®
  • AI Tools
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists

Research and Markets - Global $8.83 Billion Osteoporosis Drugs Market Growth and Demand Forecast to 2022 - Key Companies are Eli Lilly and Co, Pfizer, F. Hoffmann-La Roche, Novartis, Merck & Co. Inc., and Amgen

This image opens in the lightbox

News provided by

Research and Markets

10 May, 2017, 09:00 GMT

Share this article

Share toX

Share this article

Share toX

DUBLIN, May 10, 2017 /PRNewswire/ --

Research and Markets has announced the addition of the "Global Osteoporosis Drugs Market Size, Share, Development, Growth and Demand Forecast to 2022" report to their offering.

The global osteoporosis drugs market was worth $8,835.4 million in 2015 and it is expected to grow at a CAGR of 3.8% during 2016-2022. Among the various drug classes, the rank ligand inhibitors segment is expected to witness the fastest growth, a CAGR of 4.3% during the forecast period.

Osteoporosis disease is the most common bone disease occurring due to reduced bone mineral density, thus increasing risk of fractures and fragile bones. It leads to abnormally porous bones such as sponge, which facilitates weakening of bones and painful fracture. Bone mineral density decreases naturally with age, and hence aging population face high risks of osteoporosis. The decline in bone strength is only visible after the bone gets fractured. Most of the spine, hip, shoulder and forearm fractures occur in aged people of 65 years and above. One of the major procedures to build stronger muscle and bones is exercising regularly during the teenage years, which in turn leads to a lower risk of osteoporosis disease. The increasing trend of inactive lifestyle and obesity leads to growing prevalence of osteoporosis disease.

Some of the signs and symptoms of the osteoporosis are falling risk and fractures. Diagnostic tests of osteoporosis include X-Ray test and traditional radiography tests, which is further confirmed with the help of bone density test. Osteoporosis disease can be managed by nutrition emphasis, lifestyle management and medicines. According to National Osteoporosis Foundation, by 2025 osteoporosis would lead to approximately three million fractures.

Based on drug class, the global osteoporosis drugs market has been segmented as bisphosphonates, parathyroid hormone therapy, SERM's, rank ligand inhibitor, calcitonin, and others. The bisphosphonates segment dominated the global market in 2015.

The global osteoporosis drugs market is growing due to growing geriatric population, increasing prevalence of osteoporosis in postmenopausal women and increasing healthcare expenditure. The increasing focus on research & development of new drugs for treatment of osteoporosis and increasing awareness of osteoporosis are also driving the growth of the global osteoporosis drugs market.

The restraints for the growth of the global osteoporosis drugs market include strict regulatory requirements for the approval of drugs and patent expiry of blockbuster drugs. The side-effects and complications associated with administration of osteoporosis drugs such as nausea, ulcer in stomach and irritable bowel syndrome are also hindering the growth of the global market.

Geographically, North America is expected to continue being the largest market for osteoporosis drugs globally, during 2016-2022. It is due to growing geriatric population and increasing awareness of osteoporosis. The European osteoporosis drugs market is growing at a significant rate mainly due to growing aging population, increasing prevalence of osteoporosis in postmenopausal women and increasing awareness of osteoporosis. However, the Asia-Pacific market of osteoporosis drugs is expected to witness the highest growth during the forecast period. This is due the growing geriatric population, increasing healthcare expenditure, large pool of patients, modifying lifestyle and increasing awareness of osteoporosis in the region.

Some of the key companies operating in the global osteoporosis drugs market include Eli Lilly and Company, Pfizer Inc., F. Hoffmann-La Roche, Novartis International AG, Merck & Co. Inc., and Amgen Inc.


Key Topics Covered:

1. Research Scope And Methodology

2. Executive Summary

3. Market Outlook
3.1 Introduction
3.1.1 Causes
3.1.2 Signs And Symptoms
3.1.3 Diagnosis
3.1.4 Prevention And Treatment
3.2 Trends In The Global Osteoporosis Drug Market
3.2.1 Increasing Awareness Of Osteoporosis Care
3.3 Factors Driving Growth Of The Market And Its Impact On Market Forecast
3.3.1 Increasing Prevalence Of Osteoporosis
3.3.2 Rapid Urbanization Affecting Bone Health
3.3.3 Increasing Prevalence Of Osteoporosis In Post-Menopausal Women
3.3.4 Increasing Healthcare Expenditure
3.3.5 Growing Geriatric Population
3.3.6 Increasing R&D Investment In Drug Discovery And Development
3.3.7 Impact Analysis Of Drivers On Market Forecast
3.4 Factors Hindering Growth Of The Market And Its Impact On Market Forecast
3.4.1 Side-Effects And Complications Associated With Administration Of Osteoporosis Drug
3.4.2 Patent Expiration Of Osteoporosis Drug
3.4.3 Limited Healthcare Reimbursement
3.4.4 Impact Analysis Of Restraints On Market Forecast

4. Drug Approval Process In U.S. And Europe
4.1 Drug Approval Process In The U.S.
4.2 Drug Approval Process In The Eu

5. Global Osteoporosis Drug Market Size And Forecast (2012-2022)
5.1 Global Osteoporosis Drug Market, By Drug Type
5.2 Global Osteoporosis Drug Market, By Region

6. Global Osteoporosis Drug Market, By Drug Type
6.1 Bisphosphonates Market
6.1.1 Global Bisphosphonates Market, By Region
6.2 Parathyroid Hormone Therapy Market
6.2.1 Global Parathyroid Hormone Therapy Market, By Region
6.3 Calcitonin Market
6.3.1 Global Calcitonin Market, By Region
6.4 Selective Estrogen Receptor Modulator (Serm) Market
6.4.1 Global Serm Market, By Region
6.5 Rank Ligand Inhibitor Market
6.5.1 Global Rank Ligand Inhibitor Market, By Region

7. Global Osteoporosis Drug Market, By Geography

8. Competitive Analysis

9. Company Profiles And Strategic Developments

  • Pfizer, Inc.
  • Eli Lily And Company
  • F. Hoffmann La Roche
  • Novartis Ag
  • Merck & Co., Inc.
  • Amgen, Inc.
  • Radius Health, Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Glaxosmithkline Plc

For more information about this report visit http://www.researchandmarkets.com/research/j78qph/global

Media Contact:

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

Related Links

http://www.researchandmarkets.com

Modal title

Contact PR Newswire

  • +44 (0)20 7454 5110
    from 8 AM - 5:30 PM GMT
  • General Enquiries
  • Media Enquiries
  • Partnerships

Products

  • Content Distribution
  • Multimedia Services
  • Disclosure Services
  • Cision Communications Cloud®

About

  • About PR Newswire
  • About Cision
  • Partnering Opportunities
  • Careers
  • Accessibility Statement
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United States
  • Vietnam

My Services

  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
  • Data Privacy

Do not sell or share my personal information:

  • Submit via Privacy@cision.com 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
+44 (0)20 7454 5110
from 8 AM - 5:30 PM GMT
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 PR Newswire Europe Limited. All Rights Reserved. A Cision company.